GlassScriptPhysician profile
Harry Kopolovich
NPI 1144351156
$130,587.85
in general payments reported to CMS, 2019-2025
23 companies · $3,331 in 2025
The $3,331 reported for 2025 was more than what 97% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,342 · 2020: $11K · 2021: $27K · 2022: $37K · 2023: $29K · 2024: $19K · 2025: $3,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $7,463 · Food and Beverage: $3,217 · Consulting Fee: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,300.00 |
| Travel and Lodging | $7,462.92 |
| Food and Beverage | $3,216.53 |
| Consulting Fee | $1,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $112,404.70 | 2021-2025 | |
| Allergan, INC. | $14,684.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $666.39 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $666.36 | 2019-2024 | Xarelto |
| Integra Lifesciences Corporation | $486.42 | 2022-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Davol INC. | $227.41 | 2021 | |
| Smith+Nephew, INC. | $171.50 | 2022 | |
| Ethicon US, LLC | $170.46 | 2024 | Stratafix |
| Pfizer INC. | $135.98 | 2019-2020 | |
| Baxter Healthcare | $125.03 | 2023 | |
| Bioxcel Therapeutics, INC. | $124.09 | 2023 | Igalmi |
| Alexion Pharmaceuticals, INC. | $121.68 | 2021 | |
| Portola Pharmaceuticals, LLC | $121.58 | 2020 | |
| Abbott Laboratories | $112.47 | 2024 | I-Stat |
| Melinta Therapeutics, LLC | $91.87 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $88.50 | 2022 | |
| Chiesi USA, INC. | $63.79 | 2021 | |
| Ambu INC. | $36.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.56 | 2019-2024 | Eliquis |
| Regeneron Pharmaceuticals, INC. | $26.10 | 2021 | |
| Gilead Sciences, INC. | $14.52 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.05 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.55 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Kopolovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.